Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Clin Lymphoma Myeloma Leuk ; 22(8): 581-588, 2022 08.
Artigo em Inglês | MEDLINE | ID: mdl-35393251

RESUMO

BACKGROUND: Mycosis fungoides (MF), the most common subtype of Cutaneous T-cell lymphomas, is caused by malignant T-cell proliferations in the skin that can invade blood, lymph nodes, or viscera. Currently, data on efficacy of maintenance therapies in MF are lacking. We developed a unique protocol to use chlormethine/mechlorethamine 0.016% gel formulation as maintenance regimen for MF patients in remission. PURPOSE: To determine progression-free survival and efficacy of chlormethine/mechlorethamine as maintenance and active treatment regimens for MF. MATERIALS AND METHODS: A retrospective review of MF patients seen at Thomas Jefferson University from 2012 to 2020 was conducted. Patients of all stages treated with chlormethine/mechlorethamine as maintenance or active treatment with 2 consecutive mSWATs (modified Severity Weighted Assessment Tool) documented were included. Treatment outcomes were assessed by change in mSWAT and progression-free survival. Dermatology Life Quality Index surveys before and after treatment were analyzed. RESULTS: Of 186 MF patients, 44 met inclusion criteria. Patients on maintenance therapy had a 65.22% progression-free survival rate with median time to progression of 29.45 months. By-time analysis for responders on active and maintenance treatment showed an increased response over time. Peak responses were seen at last mSWAT recorded. Both cohorts experienced improved quality-of-life scores from initiation to discontinuation of chlormethine/mechlorethamine. CONCLUSION: Patients on maintenance and active chlormethine/mechlorethamine treatment regimens demonstrated improvement in mSWAT and quality-of-life. Chlormethine/mechlorethamine treatment showed progression-free survival for a median of 29.45 months, indicating this therapy may be an effective maintenance regimen.


Assuntos
Linfoma Cutâneo de Células T , Micose Fungoide , Neoplasias Cutâneas , Humanos , Mecloretamina/efeitos adversos , Mecloretamina/uso terapêutico , Micose Fungoide/tratamento farmacológico , Micose Fungoide/patologia , Estudos Retrospectivos , Neoplasias Cutâneas/tratamento farmacológico , Neoplasias Cutâneas/patologia
2.
Skinmed ; 19(2): 128-131, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33938435

RESUMO

Port-wine stains are capillary malformations of the skin that are typically present at birth. As maturity can lead to the development of nodularity and hypertrophy in addition to the risk of bleeding, treatment has been advocated. While the pulsed dye laser has become the standard of care for laser treatment, other lasers have also been used with varying degrees of success for recalcitrant lesions. We demonstrate the safe and effective use of a novel 585 nm diode laser for a recalcitrant facial port-wine stain in a patient.


Assuntos
Lasers de Corante/uso terapêutico , Lasers Semicondutores/uso terapêutico , Mancha Vinho do Porto/cirurgia , Adulto , Feminino , Humanos , Masculino , Mancha Vinho do Porto/patologia , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA